Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alexion Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Alexion Pharmaceuticals fell $1.31 (-1.2%) to $105.46 on light volume. Throughout the day, 927,003 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,612,300 shares. The stock ranged in price between $104.84-$107.00 after having opened the day at $107.00 as compared to the previous trading day's close of $106.77. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 42.7%,




), down 28.8%,

Ambit Biosciences



Scroll to Continue

TheStreet Recommends

), down 10.4% and

Biostar Pharmaceuticals



), down 9.1%.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $20.6 billion and is part of the health care sector. Shares are up 12.4% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Alexion Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the positive front,

GW Pharmaceuticals PLC ADR



), up 17.9%,

Prana Biotechnology



), up 17.5%,




), up 15.7% and




), up 13.6% , were all gainers within the drugs industry with

Bristol-Myers Squibb Company



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.